Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...
Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 ...
AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...
Zacks Investment Research on MSN
Here's what will drive AbbVie's top-line growth in 2026
AbbVie ABBV had an encouraging year in 2025, registering a sales growth of about 8.5% year over year at constant exchange rates. This number is impressive for a company that has been facing biosimilar ...
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” ...
MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk), ...
(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
(Reuters) - CVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will ...
AbbVie (ABBV) stock falls even as the company beat Street foecasts with its Q4 2025 results and issued a better than expected ...
Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...
(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results